PuraMed BioScience announced its plans to initiate testing of a new hemp-based epilepsy treatment in the 4th quarter of 2014.
The company plans to develop a sublingual formulation, which offers faster delivery and efficiency. Sublingual delivery also avoids the “first pass effect” that often degrades oral drugs.
In March 2014, the company set out to develop and manufacture hemp and THC-free formulations that created medicinal compounds without the “high” associated with THC-containing cannabis. The company has researched the potential efficacy of cannabinoid-based pain treatment for patients with rheumatoid arthritis and chronic back pain and found that there was high probability of success.
PuraMed BioScience is also rebranding its flagship product LipiGesic M as MigraPure.
For more information call (715) 339-6373 or viist PuraMedBioScience.comg.